By Melissa Lipman ( October 5, 2012, 9:09 PM EDT) -- The Federal Trade Commission has argued that its case over the legality of pay-for-delay settlements involving blockbuster drug Androgel is a strong candidate for high court review, but with two other petitions already pending before the justices in a separate case over the controversial patent deals, attorneys on Friday questioned the agency's position....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.